<unk>  is a human interleukin-17A antagonist that is FDA approved for the treatment of moderate to severe plaque psoriasis in adult patients.   Common adverse reactions include nasopharyngitis, diarrhea, and upper respiratory tract infection.
Secukinumab
Nebacumab
Evolocumab
Sarilumab
Burosumab
Ustekinumab
Avelumab
Dupilumab